IGF-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-08. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Yet the symbiosis raised a century-long puzzle: if multiple fungi adopted algal partners independently, the "lichen condition" might be polyphyletic. This question of how many times lichenization evolved remained speculative until the advent of molecular phylogenetics. Early lichenologists such as Walter Watson warned that symbiosis can so remodel a fungus that its ancestry becomes hard to trace. Modern molecular studies confirm the problem: convergent thallus forms have evolved repeatedly and even been lost again, making ancestry hard to infer.
While the largest part of uranium-236 has been produced by neutron capture in nuclear power reactors, that part is nearly all stored in nuclear reactors and waste repositories and has not been released to the environment. The most significant environmental contribution is the 238U(n,3n)236U reaction by fast neutrons in thermonuclear weapons. The nuclear testing of the 1940s, 1950s, and 1960s (atmospheric testing ended 1963) has raised the environmental abundance levels significantly above the expected natural levels.
Russian television presenter and journalist Ksenia Sobchak publicly criticized Peters, describing his looksmaxxing content as harmful, arguing his online image "reflects increasingly extreme views and unhealthy attitudes toward self-image." Turning Point USA spokesman Andrew Kolvet sees Peters' looksmaxxing message as part of a "giant red warning sign" reflecting "a growing mentorship vacuum among young men searching for guidance." Peters has described himself as apolitical and stated in 2026 that he "would never want to be associated with politics", which he has described as "jester", a looksmaxxing term for a "foolish waste of time". Lauren Smith wrote for Spiked that he was "seen as a player in the Very Online right" but that he was "best understood not as a right-wing thought leader" due to "only offer[ing] a parody of masculinity", while Joanna Williams wrote for The Telegraph that he had "been embraced by America's Very Online Right" and that he, Fuentes, and Tate "make the overlap between politics and appearance explicit". For the Miami New Times, Alex DeLuca wrote that he was "associated with [the] 'manosphere' and far-right extremism".
=== RBLOSUM === The original code written by Henikoff and Henikoff does not exactly act according to their paper's description of the algorithm. The BLOSUM62 from that program has been used for many years as standard. Surprisingly, the miscalculated BLOSUM62 improves search performance compared to the 2008 corrected version of the same relative entropy (RBLOSUM64). A 2018 article claims that RBLOSUM is better than BLOSUM and CorBLOSUM.
Sources: en.wikipedia.org
=== Anhydrous structure === Anhydrous Dy(ClO4)3 crystallizes in the hexagonal crystal system, space group P63/m (No. 176). It is isostructural with the anhydrous perchlorates of La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Ho and Er, and belongs to a structure family related to the UCl3 type. In this structure the Dy3+ centres are nine-coordinate. The coordination environment is formed by oxygen atoms belonging to perchlorate groups, which act as multidentate ligands and generate a three-dimensional channel-containing framework. Across the lanthanide series, the lattice parameters decrease systematically because of the lanthanide contraction.
Mestanolone, also known as methylandrostanolone and sold under the brand names Androstalone and Ermalone among others, is an androgen and anabolic steroid (AAS) medication which is mostly no longer used. It is still available for use in Japan however. It is taken by mouth. Side effects of mestanolone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. It can also cause liver damage. The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong androgenic effects and weak anabolic effects, which make it useful for producing masculine psychological and behavioral effects. The drug has no estrogenic effects. Mestanolone was discovered in 1935 and was introduced for medical use in the 1950s. In addition to its medical use, mestanolone has been used to improve physique and performance. It was used in East Germany in Olympic athletes as part of a state-sponsored doping program in the 1970s and 1980s. The drug is a controlled substance in many countries and so non-medical use is generally illicit.
== Structure == Factor VIII protein consists of six domains: A1-A2-B-A3-C1-C2, and is homologous to factor V. The A domains are homologous to the A domains of the copper-binding protein ceruloplasmin. The C domains belong to the phospholipid-binding discoidin domain family, and the C2 domain mediate membrane binding. Activation of factor VIII to factor VIIIa is done by cleavage and release of the B domain. The protein is now divided to a heavy chain, consisting of the A1-A2 domains, and a light chain, consisting of the A3-C1-C2 domains. Both form non-covalently a complex in a calcium-dependent manner. This complex is the pro-coagulant factor VIIIa.
amphoteric Also amphiprotic. (of a chemical species) Tending to behave both as an acid and as a base, depending upon the medium in which the species is situated; e.g. sulfuric acid (H2SO4) is a strong acid in water but behaves more like a base in superacids.
England and Wales Annabel Sarah Jane Berry, lately Superintendent, Hampshire Constabulary. Jason Richard Davies, Assistant Chief Constable, South Wales Police. Ian John Dawson, lately Assistant Chief Constable, Lancashire Constabulary. Andrew James Duignan, lately Detective Constable, Merseyside Police. Karen Ross Findlay, Temporary Commander, Metropolitan Police Service. Christopher James Flanagan, lately Detective Inspector, South Yorkshire Police. Matthew William Gosling, Detective Chief Inspector, Metropolitan Police Service. Kam Hare, Inspector, Greater Manchester Police. Laura Catherine Elizabeth Hart, Special Chief Inspector, Merseyside Police. Natalie Horner, Detective Constable, Durham Constabulary. Paul Joseph Martin Keasey, Superintendent, Gloucestershire Constabulary. Edward James Ough, lately Superintendent, South Wales Police. John Price, Sergeant, West Midlands Police. Hayley Jenny Annette Sewart, Detective Chief Superintendent, Metropolitan Police Service. Benjamin Daniel Snuggs, Deputy Chief Constable, Thames Valley Police. Amanda Jane Stephenson, Detective Inspector, Metropolitan Police Service. Matthew Wesley Ward, Deputy Assistant Commissioner, Metropolitan Police Service. Owen Robert Weatherill, lately Assistant Chief Constable, Hertfordshire Constabulary and National Police Co-ordination Centre. Scotland Faroque Hussain, Temporary Assistant Chief Constable, Police Service of Scotland. Carol McGuire, Chief Superintendent, Police Service of Scotland. Stephanie Rose, Police Constable, Police Service of Scotland.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.